Sanjiu Medical & Pharmaceutical’s Net Profits For 2008 Increased By Almost 80 Percent
This article was originally published in PharmAsia News
Executive Summary
In an earnings report for 2008, Sanjiu Medical & Pharmaceutical stated the company's net profits reached RMB 500 million last year, up by 77 percent year-over-year. Sanjiu also predicted that China's healthcare reforms will result in fiercer competition in the OTC sector, so the company plans to explore the medical end-user sector and to expand into markets below the county level. At the same time, the firm is preparing dermatology and cold products for new launches. (Click here for more - Chinese Language)
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.